Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure

Donatella Del Sindaco1, Maria Denitza Tinti2, Luca Monzo2, Giovanni Pulignano2,1Heart Failure Unit, Division of Cardiology, INRCA Institute of Care and Research for Elderly, Rome, Italy; 2Heart Failure Clinic, Division of Cardiology/CCU, San Camillo Hospital, Rome, ItalyAbstract: Heart failure is a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Donatella Del Sindaco, Maria Denitza Tinti, Luca Monzo, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Beta-blockers therapy older left ventricular dysfunction prognosis Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/0c077d71c9af4ddc8cfc39a16ffebb0e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0c077d71c9af4ddc8cfc39a16ffebb0e
record_format	dspace
spelling	oai:doaj.org-article:0c077d71c9af4ddc8cfc39a16ffebb0e2021-12-02T01:07:08ZClinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure1178-1998https://doaj.org/article/0c077d71c9af4ddc8cfc39a16ffebb0e2010-12-01T00:00:00Zhttps://www.dovepress.com/clinical-and-economic-aspects-of-the-use-of-nebivolol-in-the-treatment-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Donatella Del Sindaco1, Maria Denitza Tinti2, Luca Monzo2, Giovanni Pulignano2,1Heart Failure Unit, Division of Cardiology, INRCA Institute of Care and Research for Elderly, Rome, Italy; 2Heart Failure Clinic, Division of Cardiology/CCU, San Camillo Hospital, Rome, ItalyAbstract: Heart failure is a common and disabling condition with morbidity and mortality that increase dramatically with advancing age. Large observational studies, retrospective subgroup analyses and meta-analyses of clinical trials in systolic heart failure, and recently published randomized studies have provided data supporting the use of beta-blockers as a baseline therapy in heart failure in the elderly. Despite the available evidence about beta-blockers, this therapy is still less frequently used in elderly compared to younger patients. Nebivolol is a third-generation cardioselective beta-blocker with L-arginine/nitric oxide-induced vasodilatory properties, approved in Europe and several other countries for the treatment of essential hypertension, and in Europe for the treatment of stable, mild, or moderate chronic heart failure, in addition to standard therapies in elderly patients aged 70 years old or older. The effects of nebivolol on left ventricular function in elderly patients with chronic heart failure (ENECA) and the study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure (SENIORS) have been specifically aimed to assess the efficacy of beta-blockade in elderly heart failure patients. The results of these two trials demonstrate that nebivolol is well tolerated and effective in reducing mortality and morbidity in older patients, and that the beneficial clinical effect is present also in patients with mildly reduced ejection fraction. Moreover, nebivolol appears to be significantly cost-effective when prescribed in these patients. However, further targeted studies are needed to better define the efficacy as well as safety profile in frail and older patients with comorbid diseases.Keywords: beta-blockers, therapy, older, left ventricular dysfunction, prognosisDonatella Del SindacoMaria Denitza TintiLuca Monzoet alDove Medical PressarticleBeta-blockerstherapyolderleft ventricular dysfunctionprognosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 381-393 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Beta-blockers therapy older left ventricular dysfunction prognosis Geriatrics RC952-954.6
spellingShingle	Beta-blockers therapy older left ventricular dysfunction prognosis Geriatrics RC952-954.6 Donatella Del Sindaco Maria Denitza Tinti Luca Monzo et al Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
description	Donatella Del Sindaco1, Maria Denitza Tinti2, Luca Monzo2, Giovanni Pulignano2,1Heart Failure Unit, Division of Cardiology, INRCA Institute of Care and Research for Elderly, Rome, Italy; 2Heart Failure Clinic, Division of Cardiology/CCU, San Camillo Hospital, Rome, ItalyAbstract: Heart failure is a common and disabling condition with morbidity and mortality that increase dramatically with advancing age. Large observational studies, retrospective subgroup analyses and meta-analyses of clinical trials in systolic heart failure, and recently published randomized studies have provided data supporting the use of beta-blockers as a baseline therapy in heart failure in the elderly. Despite the available evidence about beta-blockers, this therapy is still less frequently used in elderly compared to younger patients. Nebivolol is a third-generation cardioselective beta-blocker with L-arginine/nitric oxide-induced vasodilatory properties, approved in Europe and several other countries for the treatment of essential hypertension, and in Europe for the treatment of stable, mild, or moderate chronic heart failure, in addition to standard therapies in elderly patients aged 70 years old or older. The effects of nebivolol on left ventricular function in elderly patients with chronic heart failure (ENECA) and the study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure (SENIORS) have been specifically aimed to assess the efficacy of beta-blockade in elderly heart failure patients. The results of these two trials demonstrate that nebivolol is well tolerated and effective in reducing mortality and morbidity in older patients, and that the beneficial clinical effect is present also in patients with mildly reduced ejection fraction. Moreover, nebivolol appears to be significantly cost-effective when prescribed in these patients. However, further targeted studies are needed to better define the efficacy as well as safety profile in frail and older patients with comorbid diseases.Keywords: beta-blockers, therapy, older, left ventricular dysfunction, prognosis
format	article
author	Donatella Del Sindaco Maria Denitza Tinti Luca Monzo et al
author_facet	Donatella Del Sindaco Maria Denitza Tinti Luca Monzo et al
author_sort	Donatella Del Sindaco
title	Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
title_short	Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
title_full	Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
title_fullStr	Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
title_full_unstemmed	Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
title_sort	clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/0c077d71c9af4ddc8cfc39a16ffebb0e
work_keys_str_mv	AT donatelladelsindaco clinicalandeconomicaspectsoftheuseofnebivololinthetreatmentofelderlypatientswithheartfailure AT mariadenitzatinti clinicalandeconomicaspectsoftheuseofnebivololinthetreatmentofelderlypatientswithheartfailure AT lucamonzo clinicalandeconomicaspectsoftheuseofnebivololinthetreatmentofelderlypatientswithheartfailure AT etal clinicalandeconomicaspectsoftheuseofnebivololinthetreatmentofelderlypatientswithheartfailure
_version_	1718403298532261888

Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure

Ejemplares similares